Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial
In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs (28.3%) over 80 weeks.
Therapeutic Area
Therapeutic area intelligence for Triple Agonist with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.